Back to homepage

Respiratory

Novel therapeutic targets for allergic airway disease in children

Authors: Alessandro Giallongo MD, Giuseppe Fabio Parisi MD, Amelia Licari MD, Giulio Pulvirenti MD, Caterina Cuppari MD, Carmelo Salpietro MD, Gian Luigi Marseglia MD, Salvatore Leonardi MD

Keywords: allergic airway disease, allergic rhinitis, asthma, biologics, children, chronic rhinosinusitis, immunotherapy. Citation: Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, Marseglia GL, Leonardia S. Novel therapeutic targets for allergic airway disease in children. Drugs in

More

Immunotherapy in inoperable stage III non-small cell lung cancer: a review

Authors: Natasha A Jain MD, Gregory A Otterson MD

This article summarizes the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III nonsmall cell lung cancer.

More

Easyhaler®: an overview of an inhaler device for day-to-day use in patients with asthma and chronic obstructive pulmonary disease

Authors: Federico Lavorini MD, PhD

The aim of this article is to provide an overview of the scientific literature on Easyhaler, with the purpose of emphasising features that make it close to the concept of an ‘ideal’ inhaler for daily use in patients with asthma or chronic obstructive pulmonary disease.

More

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice

Authors: Olalla Montero-Pérez PharmD, María Beatriz Contreras-Rey PharmD, Ernesto Sánchez-Gómez PhD

This article analyses the effectiveness, clinical outcomes, and safety of mepolizumab in clinical practice.

More

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Authors: Francesco Menzella MD, Mirella Biava Msc, Diego Bagnasco MD, PhD, Carla Galeone Msc, Anna Simonazzi MD, Patrizia Ruggiero Msc, Nicola Facciolongo MD

This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

More